178 related articles for article (PubMed ID: 25327560)
21. Haplotype structure and selection of the MDM2 oncogene in humans.
Atwal GS; Bond GL; Metsuyanim S; Papa M; Friedman E; Distelman-Menachem T; Ben Asher E; Lancet D; Ross DA; Sninsky J; White TJ; Levine AJ; Yarden R
Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4524-9. PubMed ID: 17360557
[TBL] [Abstract][Full Text] [Related]
22. MDM2 SNP309 and SNP354 are not associated with lung cancer risk.
Pine SR; Mechanic LE; Bowman ED; Welsh JA; Chanock SC; Shields PG; Harris CC
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1559-61. PubMed ID: 16896050
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population.
Ma H; Hu Z; Zhai X; Wang S; Wang X; Qin J; Jin G; Liu J; Wang X; Wei Q; Shen H
Cancer Lett; 2006 Aug; 240(2):261-7. PubMed ID: 16288830
[TBL] [Abstract][Full Text] [Related]
24. The MDM2 285G-309G haplotype is associated with an earlier age of tumour onset in patients with Li-Fraumeni syndrome.
Renaux-Petel M; Sesboüé R; Baert-Desurmont S; Vasseur S; Fourneaux S; Bessenay E; Frébourg T; Bougeard G
Fam Cancer; 2014 Mar; 13(1):127-30. PubMed ID: 23884452
[TBL] [Abstract][Full Text] [Related]
25. MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.
Paulin FE; O'Neill M; McGregor G; Cassidy A; Ashfield A; Ali CW; Munro AJ; Baker L; Purdie CA; Lane DP; Thompson AM
BMC Cancer; 2008 Oct; 8():281. PubMed ID: 18828900
[TBL] [Abstract][Full Text] [Related]
26. Association of rs2279744 and rs117039649 promoter polymorphism with the risk of gynecological cancer: A meta-analysis of case-control studies.
Zhang J; Zhang Y; Zhang Z
Medicine (Baltimore); 2018 Jan; 97(2):e9554. PubMed ID: 29480845
[TBL] [Abstract][Full Text] [Related]
27. No association between the MDM2 -309 T/G promoter polymorphism and breast cancer in African-Americans or Whites.
Millikan RC; Heard K; Winkel S; Hill EJ; Heard K; Massa B; Mayes L; Williams P; Holston R; Conway K; Edmiston S; de Cotret AR
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):175-7. PubMed ID: 16434608
[No Abstract] [Full Text] [Related]
28. A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population.
Wang M; Zhang Z; Zhu H; Fu G; Wang S; Wu D; Zhou J; Wei Q; Zhang Z
Clin Cancer Res; 2008 Jun; 14(11):3633-40. PubMed ID: 18519798
[TBL] [Abstract][Full Text] [Related]
29. Polymorphisms in NEIL-2, APE-1, CYP2E1 and MDM2 Genes are Independent Predictors of Gastric Cancer Risk in a Northern Jiangsu Population (China).
Elingarami S; Liu H; Kalinjuma AV; Hu W; Li S; He N
J Nanosci Nanotechnol; 2015 Jul; 15(7):4815-28. PubMed ID: 26373042
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
[TBL] [Abstract][Full Text] [Related]
31. MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients.
Tornesello ML; Buonaguro L; Cristillo M; Biryahwaho B; Downing R; Hatzakis A; Alessi E; Cusini M; Ruocco V; Viviano E; Romano N; Katongole-Mbidde E; Buonaguro FM
Biomarkers; 2011 Feb; 16(1):42-50. PubMed ID: 20979563
[TBL] [Abstract][Full Text] [Related]
32. Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analysis.
Yan YL; Han F; Tan WM; Wu CP; Qin X
Asian Pac J Cancer Prev; 2014; 15(16):6767-72. PubMed ID: 25169523
[TBL] [Abstract][Full Text] [Related]
33. A case-control study on the SNP309T → G and 40-bp Del1518 of the MDM2 gene and a systematic review for MDM2 polymorphisms in the patients with breast cancer.
Jalilvand A; Yari K; Aznab M; Rahimi Z; Salahshouri Far I; Mohammadi P
J Clin Lab Anal; 2020 Dec; 34(12):e23529. PubMed ID: 32951271
[TBL] [Abstract][Full Text] [Related]
34. SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers.
Okamoto K; Tsunematsu R; Tahira T; Sonoda K; Asanoma K; Yagi H; Yoneda T; Hayashi K; Wake N; Kato K
BMC Med Genet; 2015 Aug; 16():67. PubMed ID: 26293665
[TBL] [Abstract][Full Text] [Related]
35. Relationship Between Murine Double Minute 2 (MDM2) T309G Polymorphism and Endometrial Cancer Risk: A Meta-Analysis.
Xue Z; Zhu X; Teng Y
Med Sci Monit; 2016 Sep; 22():3186-90. PubMed ID: 27604213
[TBL] [Abstract][Full Text] [Related]
36. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
Wan Y; Wu W; Yin Z; Guan P; Zhou B
BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
[TBL] [Abstract][Full Text] [Related]
37. MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis.
Liu J; Zheng Y; Lei D; Liu D; Xu F; Jin T; Cao X; Zhao X; Yu X; Pan X
Asian Pac J Cancer Prev; 2011; 12(8):1899-903. PubMed ID: 22292622
[TBL] [Abstract][Full Text] [Related]
38. Current evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer risk.
Fu Q; Zhang G; Chen H; Zheng Y; Cheng J
Tumour Biol; 2013 Dec; 34(6):3721-9. PubMed ID: 23912932
[TBL] [Abstract][Full Text] [Related]
39. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
40. The association between murine double minute 2 (MDM2) rs2279744 and endometrial cancer risk in a Chinese Han population.
Wu JP; Luo X
Cell Mol Biol (Noisy-le-grand); 2017 Oct; 63(10):128-130. PubMed ID: 29096752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
